Abbott Laboratories (ABT)
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
Most companies don't survive for decades, much less pay regular dividends for that long. However, some rare corporations can pull it off.
ABT Stock Jumps 12% Since Q4 Earnings: Time to Invest in Abbott?
Abbott projects organic sales growth between 7.5% and 8.5% for 2025.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
3 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative biotech that may launch game-changing products down the road.
Why We Chose Abbott Labs Stock Amid Tariff And DeepSeek Volatility
The last few weekends have been roiled by headlines. Here's why we took a different direction on this medical stock this week.
Here are the best performing dividend aristocrats stocks in 2025
Dividend aristocrat stocks have largely done well in the past few years. The closely-followed ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has jumped by over 133% from its lowest level in 2020.
2 Unstoppable Dividend Stocks That Will Pay You for Life
In the past few years, some high-profile dividend stocks have reduced their payouts, much to the chagrin of investors. As most income seekers want to avoid this fate, they might consider turning to arguably the most elite group of dividend payers on the market: Dividend Kings.
My Best Dividend Aristocrats For February 2025
The ProShares S&P 500 Dividend Aristocrat ETF posted its 3rd worst monthly return in December, falling by 7.69%. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 42 months of tracking these strategies, two strategies are generating a CAGR superior to NOBL.
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Reasons to Retain ABT Stock in Your Portfolio Now
Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.
Is There More Upside For ABT Stock After A 10% Jump In A Week?
Abbott (NYSE: ABT) recently reported its Q4 results, with revenues marginally below and earnings meeting the street expectations. The company reported revenue of $10.97 billion and earnings of $1.34 on a per-share and adjusted basis, compared to the consensus estimates of $11.01 billion and $1.34, respectively.
Abbott Laboratories: Strong Q4 Results And Bullish Outlook
On January 22, Abbott Laboratories published financial results for the fourth quarter of 2024, initially receiving mixed reactions from Wall Street. However, its revenue was about $10.97 billion for the three months ended December 31, 2024, up 7.2% year-on-year, driven by strong sales in the company's Medical Devices segment. Moreover, Abbott expects its revenue to grow by 7.5% to 8.5% in 2025, while its adjusted diluted EPS will be between $5.05 and $5.25, implying double-digit percentage growth year-over-year.
